#AS­CO22: Merus looks to beat El­e­va­tion to NRG1+ sum­mit as BLA fil­ing ap­proach­es

CHICA­GO — Merus wants to tack­le a rare ge­nom­ic fu­sion in on­col­o­gy that im­pacts about 5,000 new pa­tients in the US each year, and the biotech thinks its in­ter­im ef­fi­ca­cy da­ta can lead zeno­cu­tuzum­ab to be­come the first ap­proved med for those pa­tients, CEO Bill Lund­berg told End­points News.

Look­ing at the da­ta from 83 evalu­able pa­tients out of 110 treat­ed as of April 12, Merus saw an over­all re­sponse rate of 34% in pa­tients with the rare fu­sion, known as NRG1+, in the biotech’s Phase I/II study and ex­pand­ed ac­cess pro­gram. Of those 83 pa­tients, 11 were part of the EAP.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER